

**Amendments to the Claims**

The following listing of claims replaces all prior versions and listings of claims in the present application.

**Listing of Claims:**

1-8. (Cancelled)

9. (Currently Amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

an amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 42 (SEQ ID NO:42), Figure 45 (SEQ ID NO:45), or Figure 47 (SEQ ID NO:47).

10. (Previously Presented) A chimeric molecule comprising a polypeptide according to Claim 9 fused to a heterologous amino acid sequence.

11. (Previously Presented) The chimeric molecule of Claim 10, wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.

12-13. (Cancelled)

14. (Previously Presented) A composition of matter comprising (a) a polypeptide of Claim 9, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, in combination with a carrier.

15. (Previously Presented) The composition of matter of Claim 14, wherein said carrier is a pharmaceutically acceptable carrier.

16. (Previously Presented) The composition of matter of Claim 15 comprising a therapeutically effective amount of (a), (b), (c) or (d).

17. (Previously Presented) An article of manufacture, comprising:

a container;

a label on said container; and

a composition of matter comprising (a) a polypeptide of Claim 9, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said container, wherein label on said container indicates that said composition of matter can be used for treating psoriasis.

18-25. (Cancelled)